ISSN: 2837-4614
DOI: 10.33552/ARM.2022.01.000501
Archives of Reproductive & Medicine
Iris Publishers

Research Article



# A Few Words about Malignancy

**Siniša Franjić***

*Independent Researcher, Republic of Croatia, Europe*

***Corresponding author:** Siniša Franjić, Independent Researcher, Republic of Croatia, Europe.

**Received Date:** May 09, 2022

**Published Date:** June 02, 2022

## Abstract

Malignancy is a term used for groups of tumors that, when spread, grow into healthy tissue, and destroy it, and by spreading through lymph and blood, they create metastases in distant organs. Metastases have the same characteristics of growth, spread and destruction of organs as a malignant primary tumor that spreads through the blood so that the outcome is usually fatal for the patient. By analogy, the term malignancy is also used for some other conditions in medicine which are not tumor processes and in which the outcome of therapy is uncertain, i.e., it has a poor prognosis.

**Keywords:** Body; Cells; Malignancy; Cancer; Tumor

## Introduction

A malignant growth is characterized by a continuing, purposeless, unwanted, uncontrolled, and damaging growth of cells that differ structurally and functionally from the normal cells from which they developed [1]. The commonly used term for a malignant growth could be a cancer – cancer is Latin for crab. The condition was called cancer in ancient times because a complicated cancer was thought to resemble a crab, with "claws" reaching out into surrounding tissues.

## Cells

All living plants and animals are composed of living cells that usually must divide to supply more cells for growth and development, and to exchange cells that are damaged or have died [1]. The method of cell proliferation (cell division and cell growth) is controlled by genes within the DNA of the cell nucleus. The genes are inherited from parents and bestow features within the offspring, including height, color, weight and countless other distinctive features and functions of the tissues. the method is generally under remarkably well-balanced control. A cancer forms when this genetic control is damaged or lost in one or more cells, which then still divide and divide again producing more abnormal cells that still divide and increase in number when and where they should not. The masses of unwanted dividing cells cause damage to other cells and tissues within the body. they're no longer controlled by normal genes that stop division after normal body needs are met. They simply go on dividing in spite of causing damage to other tissues and body functions. This is often a cancer. All the causes of cancer are now known to directly, or indirectly, damage these normal genes that regulate cell division.

One obvious factor is that the longer we live the more chance there's for the genes that regulate cell proliferation to become damaged by exposure to agents that damage the genetic blueprint, DNA. So most cancers become more common the longer we live; most cancers are more common in adulthood. Another factor is that the rate of division for growth and replacement of tissues. Tissues like skin, bowel lining or lining of air passages (especially within the lungs), and blood cells are constantly being shed and replenished. Breast cells are constantly changing thanks to hormone activity over

a woman's years of fertile life. With all this constant cell proliferation there's more likelihood of mistakes being made within the process of copying the genetic blueprint to daughter cells, especially because the process becomes less accurate as we become old. A mistake or error in copying the genetic blueprint is termed a mutation. These then are the tissues most likely to undergo malignant change. Bone growth is greatest in growing young people and testicular activity is greatest in young adult males and these are the periods of life most prone to cancers of those tissues. As men become older the slow but constant changes within the prostate gland make it more likely that factors causing a change in cells might get it wrong after years of exposure to the drive of male hormones. So prostate cancer becomes increasingly common in adulthood.

The remarkable thing isn't that something goes wrong from time to time within the delicate process of cell division but that things don't get it wrong more often. in all life there's a continuous delicate living process involving countless generations of cell division. The better we care for our bodies with good living practices the greater the likelihood of preventing something, possibly uncontrollable, from seriously going wrong.

These good living practices include having good nutrition, healthy exercise, safe sex and avoiding exposure to potentially damaging agents in the environment. All those practices serve to reduce the exposure of the genetic material in cells to agents that would cause changes within the genetic blueprint.

## Cancer Cells

A malignancy is therefore totally different from an infection, which is caused by organisms from outside the body invading body tissues and causing damage [1]. The body defenses recognize invading organisms as foreign and protective measures are set in train to destroy them. Invading cancer cells, on the other hand, are abnormal cells that have developed from the body's own cells and are therefore allowed to further develop and infiltrate other tissues without the control normally provided by natural body defenses.

Cancer cells even have different features and take on a special microscopic appearance from the cells from which they developed. Cancer cells become bizarre in size, shape, and other features. As a rule, the more bizarre they become, the more aggressive and malignant is their behavior. Cancer cells are usually derived from one original cell and are said to show a clonal origin. The nucleus is usually irregular, larger, and darker in color and will even be duplicated within the one cell. The cytoplasm is usually relatively smaller, irregular in size and shape and without the special features of the cell of origin. There are also cells not only of various sizes and shapes but also with different staining properties (pleomorphic). These changes are led to by changes within the tumor suppressor genes and oncogenes that are responsible for the control of cell division.

## Causes

For generations doctors, researchers, other health workers, philosophers, unconventional practitioners and sometimes "quacks" are trying to search out one cause for all cancers, and consequently one cure [1]. No such cause has been found and possibly none exists. many various factors initiate changes in cells that cause cancer. Current evidence would suggest that each one causes of cancer act by generating damage to the genetic blueprint of cells, specifically causing mutations in proto-oncogenes and tumor suppressor genes. In many cases the mutation in such genes is linked directly to the categories of DNA damage related to the agents that cause cancer e.g., UV-light and tobacco tar, and every has its own signature sort of DNA damage, providing evidence of "direct cause and effect". Even tumor viruses cause cancer by altering the cell's genetic blueprint, either by directly altering the expression of proto-oncogenes, or indirectly, through the inactivation of tumor suppressor proteins, in effect, over-riding the genetic blueprint. Today it's believed that cancer arises from one cell that has acquired 6–12 genetic changes (mutations) in key tumor suppressor and proto-oncogenes. This explains the clonal origin of cancers, and why cancer incidence increases with age, because of the sequential accumulation of those mutations; and, why some familial cancers are inherited at an earlier age, as such individuals would have already got one of these pre-disposing mutations at birth. While we can minimize our own risk of cancer by adopting a healthy lifestyle, we cannot eliminate the risk, as within all our cells are natural metabolites that may potentially cause such mutations.

## Deformation

The biomechanical properties of cells change as they become cancerous or are surrounded by metastatic tumor cells. e amount of cell deformation or cell stones are often an indicator to differentiate healthy and diseased cells [2]. The cytoskeletal structure and concentration of cytoskeletal content alters during cancer. The rigid and ordered structure of the cytoskeleton becomes compliant and irregular because of forces generated by changes within the mechanical properties of the cells. The deformability or compliance of tumor cells one increases, and their stones and elasticity decrease within the cancerous state. the higher deformability correlates with higher malignancy and ability of the tumor cells to metastasize to distant regions of the body. Unlike cells that become sore, the ECM (extracellular matrix) becomes steer when cancer cells become more aggressive. However, despite the dissimilarity of the stones of cancer cells and their surroundings, they need similar elects on the proliferation rate of the cells in line with results from computational modeling. The model correlates the mechanical regulation of cells with the cell shapes and sets a threshold for the scale of cell clusters. The lower the cell stones, the more this offers rise to uncontrolled growth of the cells. Metastatic potential of the so tumor cells is also because of facilitation of the migration process (due to less cell stones), especially through narrower arteries and sharper turns, which is additionally facilitated through the EMT (epithelial– mesenchymal transition) process.

## Multiple Malignancies

There is an age-specific problem associated with the association of age with multiple primary malignancies [3]. This involves

the choice whether one should consider that age at which the primary or the following tumors did occur. Conceptually, it appears reasonable to think about affected by age-related multiple primary malignancies only those patients whose first cancer was diagnosed during adulthood, but we recognize that this proposal only shifts the problem to the definition of adulthood.

One common problem within the definition of multiple primary malignancies is whether the next neoplasms are metastases of the initial one. This difference may be established with absolute certainty only the tissue of origin of the first and subsequent tumor is different (for example epithelial and mesenchymal neoplasms). Microscopy and immune-histochemistry have also helped to identify tumors of origin from different tissues. within the case of some tumors, specific characteristics, like the presence of hormone receptors in breast cancer allow establishing whether a tumor occurring in several organs may be a metastasis of the initial neoplasm.

The treatment of cancer is also itself a explanation for new cancer, and enhance the chance of a second malignancy in patients who have received antineoplastic treatment. The association of acute myelogenous leukemia with cytotoxic chemotherapy is well-known. Cervical cancer has been related to an increased risk of cancer of the bladder, small intestine, ovary, bones, and of multiple myeloma, but only in patients who had been treated with radiation therapy.

Several selection biases may convey the impression that multiple primary malignancies after diagnosis of an initial cancer. Undoubtedly, patients with a diagnosis of cancer do receive more diagnostic tests, to stage the initial cancer and to determine the presence of recurrences. These tests may reveal concomitant occult malignancies. as an example, staging of non-Hodgkin's lymphoma led to the diagnosis of variety of unsuspected renal cell carcinomas. additionally, to those diagnostic biases, there's a survival bias. That's the patients who survive the primary cancer are more likely to carry the diagnosis of subsequent cancers as a consequence of the fact that they live longer. Though not properly a "selection bias" another source of error is also the changing incidence of certain malignancies with time. for instance, non-Hodgkin's lymphoma appeared more common in patients with previous diagnosis of renal cell carcinoma, before it absolutely was realized that this association reflected the increased incidence of lymphoma within the general population during that period.

## Biomarker

Biomarker-based precision medicine is now often the quality of care for patients diagnosed with cancer [4]. Industry and government have invested heavily within the development of precision medicine, and as improved diagnostics, testing, and biomarkers become more common, existing barriers to the employment of precision medicine are eliminated. To create this, happen, there must be clear scientific communication that enhances understanding and influences clinical practice. One concern is that the high cost of latest precision medicines available for patients, which should be offset by efficiency and overall value provided to patients with cancer. Additionally, instead of testing tumor specimens just one occasion, there'll be increased reliance on dynamic biomarkers within the continuum of cancer care. This can influence existing guidelines and procedures in many hospitals, clinical practices, and insurance companies, so that patients can access the best medicine for them.

It is increasingly evident that the introduction of targeted therapies has revolutionized the management of patients with cancer. Integration of biomarkers, within the tumor and stroma, additionally to clinical characteristics, helps healthcare professionals optimize diagnosis and treatment recommendations. However, when should a physician consider the utilization of biomarkers for decision support within the continuum of cancer care? Biomarker testing are often used to help assess cancer risk, best diagnose a specific malignancy, select treatment, and/or assess the treatment response. There are many decisions that physicians must make once they use biomarker testing, not the least of which is what tests to decide on from the various now available. And once the results are in, how does the physician interpret the sometimes-massive amount of data and report them in an understandable way? How should the results be applied to patient care? Will patients be reimbursed for this selected therapy? Ultimately, physicians are increasingly expected to consider these issues within the context of biomarker testing within the continuum of cancer care.

## Alcohol

The carcinogenic mechanisms of alcohol aren't yet fully understood [5]. Until recently, it absolutely was believed that pure ethanol wasn't a carcinogen itself supported animal studies. However, new research has shown that when rats got ethanol in their drinking water, they developed malignancies. Ethanol itself can prevent DNA methylation by inhibiting S-adenosyl- l -methionine (SAM), a universal methyl group donor, which is important within the regulation of gene transcription. By inhibiting SAM synthesis, oncogenes are upregulated, and tumor-suppressor genes are downregulated. Ethanol is additionally considered to be a cocarcinogen by acting as a solvent for other carcinogens to penetrate the mucosa of upper aerodigestive organs, which could help explain the excessive risk of esophageal cancer related to alcohol drinking among cigarette smokers.

There is ample evidence from both animal studies and in vitro studies of human cells indicating that the carcinogenicity of ethanol is said to its metabolism. For instance, inhalation of acetaldehyde, the first metabolite of ethanol, in rats and hamsters resulted in increased rates of carcinomas. Acetaldehyde (AD) has been shown to be carcinogenic by interfering with DNA synthesis and repair and inducing gene mutations by interacting with DNA to create mutagenic DNA adducts. These adducts can eventually cause miscoding and permanent gene mutation if they're not removed by cellular repair mechanisms. Chronic alcohol consumption has also

been shown to induce the hepatic cytochrome P450 2E1 (CYP2E1)-dependent microsomal monooxygenase enzyme at concentrations 10–20 times on top of those without chronic alcohol consumption. The CYP2E1 enzyme generates reactive oxygen species (ROS) that lead to oxidative stress, a critical pathophysiological mechanism in cancer. Finally, heavy alcohol use can result in nutritional deficiencies caused by changes in metabolic pathways. Disruption of vitamin a metabolism in heavy drinkers may promote carcinogenesis because retinoic acid (a metabolite of the vitamin) regulates genes involved in cellular growth and differentiation. In fact, a recent study that evaluated micronutrient intake and esophageal cancer risk found a protective effect for folate, vitamin B6, and vitamin A.

## Computer-Assisted Diagnosis (CAD)

Computer-assisted diagnosis (CAD) alludes to the strategies in medication where computer algorithms and programs help doctors within the understanding of medical images [6]. Software package is getting significant research option in therapeutic imaging and has been the inspiration for advancement in various domains including image processing, AI, and clinical frameworks integration. Histological images contain large quantities of cells and various structures that are appropriated and encompassed by a range of tissues. Thus, the manual understanding of histological images is tedious and requires lots of experience. Studies show that the elucidation and scoring of strained specimens that utilized the microscope don't just work exceptional yet additionally it's a profoundly visual and conceptual procedure. no matter standardizing the scoring process, the inter-observer and interobserver reproducibility by pathologists don't seem to be perfect. Additionally, recognizing certain histological structures, like tumors, cell membranes, or nuclei, is one in all the per-requirements to malignancy evaluating in histological images. Quantitative and subjective information concerning the presence, degree, measure, and state of those structures could be a significant pointer for treatment expectation and anticipation. The advancement in image analysis method and availability of high-quality digital cameras and whole slide scanners has permitted the development of the many powerful computer-assisted approaches for histopathological image investigation. The techniques can't just offer effective and robust quantification of cell expression, yet also objectivity and reproducibility. the use of computer-assisted diagnosis of histological images permits both automation and consistent interpretation of both malignant and benign tumors. Utilization of CAD for histopathology is extensively categorized into three significant groups, first is detection and segmentation of nuclei to analyze nuclear morphology for cancer metastases detection. Second is classification, i.e., grading and identification of lesion type in histopathology image, and the last is that the disease diagnosis. Computerized tools may yield significant data for diagnosis, relying upon the evaluation of exquisite sub-visual changes within the patterns of serious structures in histopathological images that are imperceptible to or hard to determine for human vision. This will conceivably prompt to early analysis of illness.

## Immunotherapy

Immunotherapy currently has been set as a key component of therapeutic regimens of the many cancers [7]. Bone marrow transplantation (BMT) following ablative/non-myeloablative bone marrow therapies is now the quality of care of the many hematological malignancies. Similarly, donor lymphocyte infusion following failed BMT is an accepted immunotherapy for the treatment of relapsed hematological malignancies. Once cancer develops, immunotherapy helps the patient's immune system fight with tumor cells to prevent cancer progression and finally elimination of cancer. Benefits of immunotherapy don't seem to be restricted to patients with advanced stages of cancers, and in contrast, patients with early stages of cancers are good candidates for immunotherapy. Bacillus Calmette-Guerin (BCG) for early-stage bladder carcinoma and sipuleucel-T immunotherapy for castration-resistant prostate cancer are all examples of approved immunotherapies employed at different stages of urological cancers. additionally, immunotherapy offers hope for about every kind of cancers. FDA-approved immunotherapeutic drugs are now available for chronic lymphocytic leukemia (CLL), NHL, Hodgkin lymphoma (HL), acute leukemia, breast cancer, lung cancer, colorectal cancers, bladder cancer, prostate cancer, renal cell carcinoma, basal cell carcinoma, melanoma, cervical cancer, hepatocellular carcinoma, and soft-tissue tumors. Promisingly, an outsized number of immunotherapies are under investigation.

Immunotherapeutic weapons are of wide categories: immunomodulator monoclonal antibodies whether agonistic or blocking, cytokines [interleukin (IL)-2, IFN-α, IL-12, GM-CSF, and tumor necrosis factor-α (TNF)-α], therapeutic cancer vaccines particularly DC vaccines, adoptive T-cell transfer, gene therapy, and novel immune adjuvant and delivery vehicles are all available to help cancer patients. Elimination of immunosuppression and boosting of immune responses against tumor cells are what immunotherapy does. These effects of immunotherapy offer long-term antitumor immune response that fights with already established cancer, prevents its progression, and prevents new metastases. Accordingly, immunotherapy shouldn't logically become restricted to patients with advanced and metastatic cancers. Despite initial experiences with immunotherapy on patients who failed with other therapeutics, today, immunotherapy is ready to become the first-line treatment either together with other therapeutic modalities or as stand-alone therapy. additionally, to accurately measure the immunotherapy-induced tumor destruction, immune-related response criteria are developed and will be employed in clinical practice and future research.

## Cancer in Children

Cancer is predominantly a disease of aging, with a dramatic increase from age 10 to 80 years and an exponential phase from 40 to 80 years [8]. In economically advantaged countries, the median age is between 65 and 70 years. Thus, most of cancer will be considered as cancers of aging. During the first 5 years of

life, there's a peak in incidence, with a completely different group of cancers that appear to have their origin prenatally, during embryogenesis and fetal development. These early cancers could also be regarded as embryonal/fetal cancers or cancers of early growth. Many of those cancers are small, round blue-cell tumors that are characteristic of pediatric malignancies. A nadir in incidence occurs at age 10, followed by a second peak during adolescence and early adulthood, most apparent in males. During this phase, there's another set of cancers unique to the age group and to organ systems that, as a group, don't occur at the other age. This second set of age-dependent cancers could also be regarded as cancers of adult growth and maturation or young adult cancers.

As a consequence of the age relatedness, the array of cancer types in AYAs (adolescents and young adult) is distinctly different from that of the other ages. The array also varies greatly by age within the age range. for a few cancers, there are few cases within the youngest AYAs and a predominance by age 40 (e.g., breast and female genital cancers) and vice versa (e.g., lymphoma and leukemia). Others predominate within the middle of the AYA age range and are of lower incidence in younger and older persons (e.g., thyroid and testis cancer). This epidemiologic uniqueness renders the AYA age bracket deficient in specialists and experts and comparatively understudied and understood. Fortunately, an AYA oncology discipline is in evolution and expected to mend the gap.

## Conclusion

Cancer is the name for a group of related diseases, and all of them have in common that part of the cells in the body begin to divide uncontrollably without ceasing and spread to the surrounding tissue. Cancer can occur in any part of the body. Under normal circumstances, cells grow and divide to create new cells when the body needs them, and when cells age or are damaged, they die, and new cells take their place. With cancer, however, this orderly process is disrupted. Old and damaged cells survive even though they should die, and new cells form even though they are not needed. Due to uncontrolled division, cells accumulate, which manifests itself as the formation of tumors. Cancer is a malignant tumor, meaning that cancer cells can spread to or invade surrounding tissue.

## Acknowledgement

None.

## Conflict of Interest

No conflict of interest.

## References

1. Stephens FO, Aigner KR (2009) Basics of Oncology. Springer-Verlag Berlin Heidelberg Berlin Germany, pp. 3-9.
2. Pourmohammadali H, Kohandel M, Sivaloganathan S (2018) Biomechanics of Cancer" in Al-Mayah, A. (Eds.): Biomechanics of Soft Tissues - Principles and Applications. CRC Press, Taylor & Francis Group, Boca Raton, USA, pp. 98.
3. Balducci L, Aapro M (2005) "Epidemiology of Cancer and Aging" in Balducci L, Extermann, M "Biological Basis of Geriatric Oncology Cancer Treatment and Research", Springer Science + Business Media, Inc., Boston, USA, pp. 6.
4. Perez EA (2019) "Biomarkers and Precision Medicine in Oncology Practice and Clinical Trials" in Ramirez AG, Trapido EJ "Advancing the Science of Cancer in Latinos", Springer Nature Switzerland AG, Cham, Switzerland, pp. 113-114.
5. Layton J, Zhang J (2013) "Alcohol Intake and Esophageal Cancer: Epidemiologic Evidence" in Embryopathy" in Watson RR, Preedy VR, Zibadi S "Alcohol, Nutrition, and Health Consequences", Springer Science+Business Media, New York, USA, pp. 461-462.
6. Makwana G, Yadav RN, Gupta L (2021) "Histopathological Image Analysis and Classification Techniques for Breast Cancer Detection" in Bajaj V, Sinha GR "Analysis of Medical Modalities for Improved Diagnosis in Modern Healthcare", CRC Press, Taylor & Francis Group, LLC; Boca Raton, USA, pp. 163.
7. Aryan Z, Keshavarz-Fathi M, Mellstedt H, Rezaei N (2020) "Cancer Immunotherapy Confers a Global Beneft" in Rezaei N "Cancer Immunology - Cancer Immunotherapy for Organ-Specific Tumors, Second Edition", Springer Nature Switzerland AG, Cham, Switzerland, pp. 11.
8. Ries L, Trama A, Nakata K, Gatta G, Botta L et al. (2016) "Cancer Incidence, Survival, and Mortality Among Adolescents and Young Adults" in Bleyer A, Barr R, Ries L, Whelan J, Ferrari A "Cancer in Adolescents and Young Adults, Second Edition", Springer International Publishing AG, Cham, Switzerland, pp. 34-37.